Sign up

Siren, L.L.C.

$4.9B assets · 115 holdings · Q2 2026 · Filed 13 AUG 2026

About Siren, L.L.C.’s 13F portfolio

Siren, L.L.C. is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Siren, L.L.C. reported $4.9B across 115 US-listed positions (). Its largest position is Scholar Rock Holding Corp (SRRK) at 11% of the reported book, and its ten biggest holdings make up 45% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$4.9B
Assets (13F)
#823
of 8,839 by size
115
Holdings
45%
Top-10 weight
56
Buys
31
Sells
Top holdings · Q2 2026
115 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: SRRK
Scholar Rock Holding Corp
$50.37
+4.94%
11%
9.6M$526.6M
2
NASDAQ: KYMR
Kymera Therapeutics Inc
$119.39
−1.44%
6.8%
2.9M$336.7M
3
NASDAQ: ERAS
Erasca Inc
$14.22
+3.34%
4.2%
11.4M$208.8M
4
NYSE: MANE
Veradermics Inc
—
—
4.1%
1.7M$203.5M
5
NASDAQ: TNGX
Tango Therapeutics Inc
$22.71
+3.75%
3.9%
6.2M$193.2M
6
NASDAQ: RVMD
Revolution Medicines Inc
$159.43
−0.24%
3.4%
900K$168.6M
7
NASDAQ: BCAX
Bicara Therapeutics Inc
$9.12
−2.77%
3.4%
5.6M$166.4M
8
NASDAQ: ARWR
Arrowhead Pharmaceuticals Inc
$43.65
+1.25%
2.8%
1.7M$139.8M
9
NASDAQ: ONC
BeOne Medicines AG
$399.70
−0.97%
2.7%
465K$132.5M
10
NASDAQ: EWTX
Edgewise Therapeutics Inc
$41.17
−0.48%
2.6%
3.2M$129.4M
11
NASDAQ: RYTM
Rhythm Pharmaceuticals Inc
$116.80
−1.88%
2.6%
1.1M$126.2M
12
NASDAQ: LXRX
Lexicon Pharmaceuticals Inc
$1.67
−2.91%
2.2%
44.3M$106.3M
13
NASDAQ: ELVN
Enliven Therapeutics Inc
$46.41
+3.39%
1.8%
1.8M$90.1M
14
NASDAQ: SYRE
Spyre Therapeutics Inc
$97.63
−3.77%
1.7%
969K$86.0M
15
NASDAQ: PBLS
Parabilis Medicines Inc
—
—
1.7%
3.0M$81.9M
16
NASDAQ: XENE
Xenon Pharmaceuticals Inc
$37.56
−0.50%
1.6%
1.3M$79.6M
17
NASDAQ: SLDB
Solid Biosciences Inc
$6.44
+1.42%
1.6%
7.7M$76.8M
18
NASDAQ: ABVX
Abivax SA
$80.65
−3.79%
1.6%
576K$76.8M
19
NASDAQ: COAG
Hemab Therapeutics Holdings Inc
—
—
1.6%
2.1M$76.6M
20
NYSE: RCUS
Arcus Biosciences Inc
$15.78
+0.13%
1.5%
2.4M$74.6M
21
NASDAQ: COGT
Cogent Biosciences Inc
$27.74
−0.25%
1.5%
1.9M$72.0M
22
NASDAQ: RLAY
Relay Therapeutics Inc
$15.91
−3.63%
1.4%
3.6M$68.3M
23
NASDAQ: TSHA
Taysha Gene Therapies Inc
$3.77
−5.51%
1.4%
9.8M$67.1M
24
NASDAQ: DFTX
Definium Therapeutics Inc
—
—
1.4%
1.4M$66.8M
25
NASDAQ: STOK
Stoke Therapeutics Inc
$26.93
+0.90%
1.3%
2.0M$65.3M

Showing 1–25 of 115 positions on this page reported in this 13F.

Sector allocation
  • Healthcare82%
  • Technology3.5%
  • Communication Services1.9%
  • Financial Services0.9%
  • Consumer Cyclical0.4%
  • Real Estate0.0%
Recent activity · vs 2026-03-31
Bought56
  • AddedERASErasca Inc+1.4%$208.8M
  • AddedMANEVeradermics Inc+10.0%$203.5M
  • AddedTNGXTango Therapeutics Inc+9.2%$193.2M
  • AddedARWRArrowhead Pharmaceuticals Inc+6.2%$139.8M
  • AddedRYTMRhythm Pharmaceuticals Inc+56.6%$126.2M
  • AddedELVNEnliven Therapeutics Inc+138%$90.1M
  • AddedSYRESpyre Therapeutics Inc+18.3%$86.0M
  • NewPBLSParabilis Medicines Inc—$81.9M
  • NewABVXAbivax SA—$76.8M
  • NewCOAGHemab Therapeutics Holdings Inc—$76.6M
Sold31
  • ReducedSRRKScholar Rock Holding Corp−11.5%$526.6M
  • ReducedKYMRKymera Therapeutics Inc−7.9%$336.7M
  • ReducedRVMDRevolution Medicines Inc−19.0%$168.6M
  • ReducedBCAXBicara Therapeutics Inc−3.4%$166.4M
  • ReducedEWTXEdgewise Therapeutics Inc−28.1%$129.4M
  • ReducedRCUSArcus Biosciences Inc−19.5%$74.6M
  • ReducedIRONDisc Medicine Inc−10.1%$65.0M
  • ReducedSEPNSepterna Inc−5.0%$63.6M
  • ReducedCRNXCrinetics Pharmaceuticals Inc−25.4%$53.2M
  • ReducedDYNDyne Therapeutics, Inc−4.5%$47.3M

Reading Siren, L.L.C.’s 13F portfolio

Siren, L.L.C.’s $4.9B 13F book is spread across 115 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 45%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are SRRK, KYMR, ERAS, MANE and TNGX, led by Scholar Rock Holding Corp (SRRK) at 11% of the portfolio. The heaviest sector exposure is Healthcare (82%), then Technology (4%).

What Siren, L.L.C. changed last quarter

Between 2026-03-31 and Q2 2026, Siren, L.L.C. was a net buyer: it opened 25 new positions and added to 31 more, while trimming 21 and closing 10 outright. Against a 115-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was Erasca Inc (ERAS), and its biggest reduction was Scholar Rock Holding Corp (SRRK).

What a 13F does and doesn’t reveal

A 13F captures only Siren, L.L.C.’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Siren, L.L.C. is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Siren, L.L.C.'s profile on this page is built directly from those filings.

How current is the 13F data on Siren, L.L.C.'s page?

It reflects Siren, L.L.C.'s most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Siren, L.L.C. files its next quarterly report, this page refreshes automatically.

Can I see Siren, L.L.C.'s complete list of holdings?

This page highlights Siren, L.L.C.'s largest positions rather than all 115 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Siren, L.L.C.'s filings.

Does a 13F show everything Siren, L.L.C. owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Siren, L.L.C.'s book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Siren, L.L.C. made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.